Dipal Doshi News Today

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,800 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.00, for a total transaction of $27,000.00. Following the transaction, the chief executive officer now owns 338,575 shares in the company, […]

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,800 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.00, for a total transaction of $27,000.00. Following the transaction, the chief executive officer now owns 338,575 shares in the company, […]

BOSTON, May 16, 2024 -- Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage...

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $15.99, for a total transaction of $15,990.00. Following the completion of the transaction, the chief executive officer now directly […]

- With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving...

Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in 

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $16.23, for a total transaction of $16,230.00. Following the completion of the sale, the chief executive officer now directly owns 246,279 […]

– Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada's transition to a clinical-stage company – – Expanded the Company's Duchenne franchise with

– Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company –